- Home
- ULS vs ILMN Comparison
ULS vs ILMN Comparison
Compare ULS & ILMN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ULS
- ILMN
- Stock Information
- Founded
- ULS 1894
- ILMN 1998
- Country
- ULS United States
- ILMN United States
- Employees
- ULS 15094
- ILMN N/A
- Industry
- ULS
- ILMN Medical Specialities
- Sector
- ULS
- ILMN Health Care
- Exchange
- ULS Nasdaq
- ILMN Nasdaq
- Market Cap
- ULS 14.6B
- ILMN 13.1B
- IPO Year
- ULS 2024
- ILMN 2000
- Fundamental
- Price
- ULS $69.85
- ILMN $98.15
- Analyst Decision
- ULS Buy
- ILMN Buy
- Analyst Count
- ULS 7
- ILMN 16
- Target Price
- ULS $69.43
- ILMN $126.88
- AVG Volume (30 Days)
- ULS 688.3K
- ILMN 2.3M
- Earning Date
- ULS 07-30-2025
- ILMN 08-05-2025
- Dividend Yield
- ULS 0.74%
- ILMN N/A
- EPS Growth
- ULS 28.34
- ILMN N/A
- EPS
- ULS 1.67
- ILMN N/A
- Revenue
- ULS $2,905,000,000.00
- ILMN $4,337,000,000.00
- Revenue This Year
- ULS $6.76
- ILMN N/A
- Revenue Next Year
- ULS $6.04
- ILMN $3.11
- P/E Ratio
- ULS $41.91
- ILMN N/A
- Revenue Growth
- ULS 6.84
- ILMN N/A
- 52 Week Low
- ULS $40.99
- ILMN $68.70
- 52 Week High
- ULS $73.98
- ILMN $156.66
- Technical
- Relative Strength Index (RSI)
- ULS N/A
- ILMN 77.43
- Support Level
- ULS N/A
- ILMN $88.68
- Resistance Level
- ULS N/A
- ILMN $95.99
- Average True Range (ATR)
- ULS 0.00
- ILMN 2.92
- MACD
- ULS 0.00
- ILMN 0.67
- Stochastic Oscillator
- ULS 0.00
- ILMN 86.09
About ULS UL Solutions Inc.
UL Solutions is a global leader specializing in a broad range of product testing, inspection, and certification services. UL Solutions is the for-profit branch out of three organizations under the UL Enterprise. TIC operations make up nearly all of UL Solutions' total revenue and are composed of two segments: industrial and consumer. UL Solutions' remaining business includes software and advisory, which complements its core TIC offerings. The firm operates globally.
About ILMN Illumina Inc.
Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (9% of 2024 sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.